Pursuant to 21 CFR 1301.33(a), this is notice that on June 7, 2004, Johnson Matthey Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, New Jersey 08066, made application by letter to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of Dihydromorphine (9145), a basic class of controlled substance listed in Schedule I.
The company plans to manufacturer Dihydromorphine for internal use in production of other controlled substances for distribution to its customers.
Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).
Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistance Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCD) and must be filed not later than September 20, 2004.Start Signature
Dated: July 8, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. 04-16386 Filed 7-19-04; 8:45 am]
BILLING CODE 4410-09-M